Solventum Corporation
NYSE:SOLVMedical - Care Facilities
-$2.00 today
- Market cap
- $14.70B
- Beta
- 0.75
- P/E (TTM)
- 9.1
- EPS (TTM)
- $8.22
Volume 0.76M
Average 1.70M
SOLV Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Solventum CorporationNYSE: SOLV
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $927M rose 20.1% year over year, ahead of the +8.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 12.1% from the prior quarter. Over 3 fiscal years it compounded at +11.3% a year.
Context
- Selling, general & admin amounted to 37.0% of revenue in FY2025, up 3.3 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 11 analysts of $2.53B (-17.8%) for the fiscal year ending Dec 2026, a slowdown from the +10.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $927M+12.1% QoQ
- Last fiscal yearDec 2025
- $3.08B+10.7% YoY
- LTMJun 2026
- $3.29B+8.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 3.08B USD
- Year-over-year change
- +10.7%
- 4-year CAGR
- +7.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.08B | +10.7% |
| FY2024 | 2024-12-31 | 2.78B | +24.0% |
| FY2023 | 2023-12-31 | 2.24B | +0.4% |
| FY2022 | 2022-12-31 | 2.24B | -1.9% |
| FY2021 | 2021-12-31 | 2.28B | — |
Selling, General & Admin vs competitors
How SOLV compares with its peers on the latest reported figures
- SOLV's LTM Jun 2026 selling, general & admin of $3.29B is the 2nd highest of the 10 companies compared; the peer median is $1.44B.
- Its year-over-year change of +8.8% is the 3rd highest of 10, against a peer median of -0.1%.
- Selling, general & admin amounts to 39.6% of revenue for SOLV, versus a peer median of 28.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $5.17B | -2.1% | +1.7% | 25.6% | |
| LTM Jun 2026 | $3.29B | +8.8% | +11.3% | 39.6% | |
| LTM Jun 2026 | $3.2B | +7.6% | +4.4% | 23.5% | |
| LTM Jun 2026 | $2.93B | -0.1% | -2.3% | 25.6% | |
| LTM Jul 2026 | $1.89B | +17.9% | +6.6% | 44.5% | |
| LTM Mar 2026 | $1.44B | -7.1% | -3.3% | 39.0% | |
| LTM Oct 2026 | $1.18B | +5.3% | +4.0% | 41.1% | |
| LTM Jun 2026 | $615.07M | -3.6% | +0.9% | 28.5% | |
| LTM Sep 2026 | $481.78M | +9.7% | +9.9% | 29.9% | |
| LTM Mar 2026 | $8.65M | -32.6% | -13.1% | 23.0% | |
| Peer median (excluding SOLV) | $1.44B | -0.1% | +1.7% | 28.5% | |
Competitors are the stored peer set for SOLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8.17B | 8.13B | 8.2B | 8.25B | 8.33B |
| Cost of Revenue | 3.25B | 3.44B | 3.5B | 3.66B | 3.87B |
| Gross Profit | 4.92B | 4.7B | 4.69B | 4.59B | 4.45B |
| Gross Margin | 60.2% | 57.7% | 57.3% | 55.6% | 53.5% |
| Research & Development | 766M | 767M | 758M | 775M | 739M |
| Selling, General & Admin | 2.28B | 2.24B | 2.24B | 2.78B | 3.08B |
| Operating Expenses | 3.04B | 3B | 3B | 3.56B | 2.27B |
| Depreciation & Amortization | 597M | 578M | 561M | 555M | 489M |
| EBITDA | 2.48B | 2.27B | 2.23B | 1.53B | 2.55B |
| EBITDA Margin | 30.3% | 27.9% | 27.2% | 18.5% | 30.6% |
| Operating Income | 1.88B | 1.69B | 1.69B | 1.04B | 2.18B |
| Operating Margin | 23.0% | 20.8% | 20.6% | 12.6% | 26.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 367M | 347M |
| Other Income / Expenses | 3M | (1M) | (25M) | (431M) | (468M) |
| Income Before Tax | 1.88B | 1.69B | 1.67B | 605M | 1.71B |
| Pre-Tax Margin | 23.0% | 20.8% | 20.3% | 7.3% | 20.6% |
| Income Tax Expense | 422M | 349M | 321M | 127M | 157M |
| Net Income | 1.46B | 1.34B | 1.35B | 479M | 1.56B |
| Net Margin | 17.9% | 16.5% | 16.4% | 5.8% | 18.7% |
| EPS (Basic) | 8.47 | 7.79 | 7.79 | 2.77 | 8.94 |
| EPS (Diluted) | 8.47 | 7.79 | 7.79 | 2.76 | 8.88 |
| Weighted Avg Shares | 172.47M | 172.47M | 172.71M | 173.2M | 174.1M |
| Weighted Avg Shares (Diluted) | 172.47M | 172.47M | 172.71M | 173.7M | 175.3M |
Solventum Corporation
NYSE:SOLV
Intrinsic Alpha fair value
Locked
Current Price
$86.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.